Searchable abstracts of presentations at key conferences in endocrinology

ea0062oc6 | Oral Communications | EU2019

Effective novel therapy in the use of managing refractory hypoglycaemia in a patient with metastatic insulinoma

Anandappa Samantha , McGowan Barbara , Prachalias Andreas , Sarker Debashis , Miquel Rosa , Carroll Paul , Velusamy Anand

Case history: 22 year old female presented with left sided hemiparesis following a generalised seizure; the blood glucose was 1.2 mmol/l. Corrective treatment restored cerebral function. In the preceding 6 months, she had symptoms of drowsiness on waking which corrected with sugary drinks and described tiredness with lethargy. There had been no reported change in appetite or bowel habits however, there had been a degree of weight loss during this period. During hospital admiss...

ea0072p14 | (1) | UKINETS2020

Effective multimodality therapy for a metastatic insulin-secreting pancreatic neuroendocrine tumour (NET): A case report

Ting Jonathan , Kapiris Matthaios , Prachalias Andreas , Velusamy Anand , McGowan Barbara , Carroll Paul , Miquel Rosa , Thillai Kiruthikah , Sarker Debashis

A 23-year-old woman presented in May 2018 with acute left-sided hemiparesis following increasingly frequent episodes of morning drowsiness with associated weight loss. She had no significant past medical history or family history. Brain imaging excluded intracranial pathology. Blood tests during a spontaneous hypoglycaemic episode (1.5 mmol/l) identified significant hyperinsulinaemic hypoglycaemia [insulin 392 pmol/l (18–173) and C-peptide 3913 pmol/l (370–1470)]. MR...

ea0080p5 | Abstracts | UKINETS2021

Real world overall survival in patients with gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) in a large United Kingdom (UK) tertiary centre

Clement Dominique , Brown Sarah , Halim Mohammed , Dolly Saoirse , Kibriya Nabil , Howard Mark , Prachalias Andreas , Menon Krishna , Srinivasan Parthi , Ramage John , Srirajaskanthan Raj

Introduction: The incidence and prevalence of GEP-NENs is rising worldwide. NENs represent the group off well differentiated neuroendocrine tumours (NET) and poorly differentiated neuroendocrine carcinoma (NEC). NETs can be divided into grade 1 (G1), grade 2 (G2) and grade 3 (G3) based on histological parameters. There exist several studies regarding survival data but these are mainly based on national databases.Aim: To describe the real world overall su...

ea0046oc2 | (1) | UKINETS2016

Tumour size is not a reliable criterion for management of patients with Non-secreting pancreatic neuroendocrine tumours: results of a large, multi-centre, operative cohort

Mills Logan , Drymousis Panagiotis , Vashist J , Burdelski C , Prachalias Andreas , Srinivasan Parthi , Menon Krishna , Khan Saboor , Cave Judith , Armstrong Thomas , Weickert MO , Frilling Andreja , Ramage JK , Srirajaskanthan Raj

Background: Small pancreatic neuroendocrine tumours (PNETs) present a management dilemma because of their uncertain natural history. Some clinicians believe that lesions <2 cm are indolent and can be managed with surveillance. By contrast, the most recent WHO classification system regards all PNETs as potentially malignant.Aim: To assess the malignant behaviour of small PNETs in a large, retrospective, multicentre patient cohort.<p class="abstext...

ea0068oc2 | Abstracts | UKINETS2019

Development of ex-vivo models of metastatic neuroendocrine neoplasms

Doornebal Ewald , Harris Nicola , Edwards Helen , Miquel Rosa , Zen Yoh , Pizanias Michail , Prachalias Andreas , Menon Krishna , Zamalloa Ane , Preziosi Melissa , Heaton Nigel , Ramage John K , Williams Roger , Palma Elena , Chokshi Shilpa , Srirajaskanthan Raj

Background: The lack of relevant in-vivo and in-vitro models has precluded investigations of the pathophysiology of metastatic NENs. Organotypic tumour slices retain the complexity of tumours in-vivo without extensive manipulation of the tissue. The aims of this study are to understand the utility of precision cut slice technology to develop an immunocompetent model of metastatic GEP NENs to test new therapeutics and elucidate immunological, molecula...

ea0072oc1 | Oral Communications | UKINETS2020

Identification of soluble immune checkpoint receptor landscape in liver metastases of neuroendocrine neoplasms: A new perspective for immunotherapy

Doornebal Ewald , Harris Nicola , Riva Antonio , Pizanias Michail , Phillips Sandra , Zen Yoh , Sticova Eva , Prachalias Andreas , Menon Krishna , Zamalloa Ane , Preziosi Melissa , Heaton Nigel , Eaton Simon , Ramage John , Williams Roger , Palma Elena , Srirajaskanthan Rajaventhan , Chokshi Shilpa

Accumulating evidence suggests that the immunological landscape plays a key role in the progression of neuroendocrine liver metastases (LM-NENs), which is often characterised by immune cell infiltration. Anti-tumour functions of infiltrating lymphocytes are often silenced through hyper-expression of inhibitory checkpoint receptors (CRs) such as PD-1, but favourable outcomes with anti-PD-1 therapy have been low. Recently, functional soluble (cell-free) CRs beyond PD-1 have been...

ea0060p18 | (1) | UKINETS2018

The impact of 68Ga-based PET-CT scanning on the management of patients with sporadic pancreatic neuroendocrine tumours (pNETs)

Cuthbertson Daniel , Barriuso Jorge , Pizanais Michail , Jaffa Matthew , Lamarca Angela , Vivian Gillian , Halloran Tom , Westwood Tom , Prachalias Andreas , O'Reilly Derek , Weismann Hulya , Martin Wendy , Vinjamuri Sobhan , Pritchard D Mark , Hubner Richard , Srirajaskanthan Raj , Ramage John , Raraty Mike , Ganeh Paula , Fenwick Steve , Valle Juan , Yip Vincent

Background: Pancreatic neuroendocrine tumours (panNETs) are rare tumours (prevalence 4/100,000). Diagnosis and staging of panNETs requires biochemical screening, cross-sectional imaging (with CT/MRI), endoscopic ultrasound (EUS) and where available, functional imaging using 68Ga-labelled synthetic octreotide analogues using PET-CT due to its reported higher sensitivity and specificity.Methods: A retrospective, electronic case note study was ca...

ea0060p30 | (1) | UKINETS2018

The impact of 68Ga-based PET-CT scanning on the management of patients with familial pancreatic neuroendocrine tumours (panNETs)

Cuthbertson Daniel , Barriuso Jorge , Pizanias Michail , Jaffa Matthew , Nuttall Christina , Vivian Gillian , Halloran Tom , Westwood Tom , Prachalias Andreas , Lalloo Fiona , Weismann Hulya , Martin Wendy , Vinjamuri Sobhan , Mark Pritchard D. , Fenwick Steve , Ganeh Paula , Raraty Mike , McNamara Mairead , Srirajaskanthan Raj , Ramage John , Manoharan Prakash , Yip Vincent

Background: Pancreatic neuroendocrine tumours (panNETs) may arise as part of an underlying genetic condition such as multiple endocrine neoplasia type 1 (MEN type 1). The value of functional imaging using 68Ga-labelled synthetic octreotide analogues using PET-CT has not been extensively evaluated in patients with MEN1 to determine its value.Methods: We investigated the effect of 68Ga-based PET-CT imaging on patient management in pat...

ea0056p140 | Endocrine tumours and neoplasia | ECE2018

Achievement of therapeutic mitotane concentrations in management of advanced adrenocortical cancer: a single centre experience in 47 patients

Bakhit Mohamed , Whitelaw Benjamin C , Gilbert Jackie , Coskeran Patsy , Diaz-Cano Salvador , Taylor David R , Taylor Norman T , Ghatore Lea , Lewis Dylan , Vivian Gillian , Sarker Debashis , Ross Paul , Davis Laura May , Clough Jennifer , Hubbard Johnathan G , Galata Gabriele , Prachalias Andreas , Schulte Klaus-Martin , Aylwin Simon J B

Introduction: Multi-modal therapy for adrenocortical carcinoma (ACC) includes surgery, therapy with the adrenolytic agent mitotane and systemic chemotherapy. Achievement of therapeutic mitotane concentrations (≥14 mg/l) has been related to improved outcomes.Aim: To evaluate the effectiveness of a defined* high dose protocol mitotane therapy in patients with advanced ACC (stages III and IV).Methods: Review of patients presenti...